Progressive Multifocal Leukoencephalopathy (PML)

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Overview

Progressive Multifocal Leukoencephalopathy (PML) is a rare, severe, and often fatal demyelinating disease of the central nervous system caused by reactivation of the JC virus (JCV), a ubiquitous human polyomavirus. [1] The disease occurs almost exclusively in immunocompromised individuals and is characterized by progressive neurological deterioration associated with multifocal white matter lesions visible on neuroimaging.

Historically, PML was predominantly associated with advanced HIV/AIDS, occurring in 1-5% of untreated patients. [2] However, the landscape has shifted dramatically with the introduction of disease-modifying therapies for autoimmune conditions. PML is now a critical concern in patients with multiple sclerosis treated with natalizumab (Tysabri), where the risk can reach approximately 4 per 1000 patients, particularly in those who are JCV antibody-positive with prolonged treatment duration exceeding 24 months. [3]

The prognosis remains guarded, with mortality rates ranging from 30-50% despite immune reconstitution, and survivors frequently experiencing significant permanent neurological disability. [4] Early recognition and prompt intervention—particularly cessation of immunosuppressive agents and immune system restoration—are critical for optimizing outcomes.

---

2. Epidemiology

Prevalence and Incidence

PML is rare in the general population but has well-defined high-risk groups. The overall incidence in the general population is estimated at less than 1 per million. [5]

JC Virus Seroprevalence

JC virus is ubiquitous, with seroprevalence (presence of antibodies) ranging from 50-80% in the general adult population globally. [10] Primary infection typically occurs in childhood, is usually asymptomatic, and establishes latency in kidneys, bone marrow, and possibly lymphoid tissue. The vast majority of seropositive individuals will never develop PML, highlighting the critical role of immune surveillance in preventing viral reactivation.

Demographics

• Age: Most commonly affects adults aged 40-60 years, though can occur at any age in immunocompromised individuals
• Sex: Slight male predominance in HIV-associated cases; equal distribution in iatrogenic cases
• Geographic distribution: Worldwide, paralleling JCV seroprevalence and immunosuppressive medication use

Trends Over Time

The epidemiology has evolved significantly:

• 1980s-1990s: PML emerged as a major AIDS-defining illness
• Post-1996: Dramatic reduction in HIV-associated PML following widespread HAART introduction [6]
• 2000s-present: Shift toward iatrogenic PML associated with monoclonal antibodies and disease-modifying therapies for autoimmune conditions [3,9]

---

3. Aetiology & Pathophysiology

The JC Virus (JCV)

JC virus (named after the initials of the patient from whom it was first isolated, John Cunningham) is a non-enveloped, double-stranded DNA virus belonging to the Polyomaviridae family, genus Betapolyomavirus. [1]

Key Characteristics:

• Genome: Circular dsDNA approximately 5.1 kb
• Capsid: Icosahedral, 40-45 nm diameter
• Primary infection: Usually asymptomatic in childhood
• Latency sites: Kidneys (renal tubular epithelial cells), bone marrow, lymphoid organs
• Shedding: Intermittent urinary shedding in 20-30% of healthy adults [10]

Molecular Pathogenesis

Exam Detail: 1. Viral Reactivation and Neurotropism

In the setting of severe immunosuppression—particularly impaired T-cell function—latent JCV can reactivate. The mechanisms facilitating CNS entry remain incompletely understood but likely involve:

• Hematogenous spread of reactivated virus from peripheral sites
• Infection of B lymphocytes or CD34+ hematopoietic progenitor cells serving as "Trojan horses" [11]
• Crossing of the blood-brain barrier facilitated by infected immune cells

2. CNS Cell Tropism

Once in the CNS, JCV exhibits selective tropism:

• Oligodendrocytes (primary target): Myelin-producing cells; lytic infection leads to demyelination
• Astrocytes: Can be infected, leading to bizarre, enlarged astrocytes visible on histology
• Neurons: Generally spared, though granule cell neuronopathy can occur (rare variant)

3. Lytic Infection Cycle

JCV replicates within oligodendrocyte nuclei, leading to:

• Accumulation of viral particles and disruption of cellular machinery
• Cell lysis and release of progeny virions
• Spread to adjacent oligodendrocytes
• Progressive, multifocal areas of demyelination without significant inflammation (in immunosuppressed state)

4. Host Immune Response

• Immunocompromised state: Minimal inflammatory response, allowing unchecked viral replication
• Immune reconstitution: Restoration of immune function (e.g., with HAART or cessation of immunosuppressants) can trigger vigorous immune response, leading to IRIS (see Management section)

5. Histopathological Triad

Classic PML histology demonstrates:

1. Demyelination: Multifocal areas of myelin loss
2. Bizarre astrocytes: Enlarged, atypical astrocytes with hyperchromatic nuclei
3. Oligodendrocyte nuclear inclusions: Enlarged nuclei with ground-glass appearance containing viral particles visible on electron microscopy

Risk Factors for PML Development

---

4. Clinical Presentation

PML presents with subacute progressive neurological deficits evolving over weeks to months. The presentation is highly variable, depending on the location and extent of demyelinating lesions. Unlike acute stroke, symptoms progress gradually; unlike MS relapses, there is typically no improvement or plateau.

Cardinal Symptoms and Signs

Distinctive Clinical Features

Alien Hand Syndrome: A rare but distinctive feature where the patient experiences their limb moving involuntarily or feeling disconnected from their control, typically associated with parietal lobe involvement. [14]

Rapid Progressive Dementia: Particularly in HIV-associated PML, can mimic rapidly progressive dementia syndromes.

Absence of Systemic Features: Unlike many opportunistic infections, PML typically does not cause fever, headache, or meningismus. Presence of these features should prompt consideration of alternative diagnoses or co-infection.

Temporal Pattern

• Onset: Insidious, often initially subtle and attributed to other causes
• Progression: Relentlessly progressive over weeks to months without treatment
• Plateau: Rarely, may stabilize if immune function improves
• Improvement: Uncommon without immune reconstitution; may improve in 20-30% with successful immune restoration [4]

Clinical Examination Findings

1. Higher Functions: Impaired attention, memory, executive function; MMSE/MoCA decline
2. Visual Fields: Homonymous hemianopia or quadrantanopia (posterior lesions)
3. Cranial Nerves: Usually spared (helps differentiate from brainstem stroke)
4. Motor: Upper motor neuron pattern weakness (increased tone, hyperreflexia, extensor plantars)
5. Sensory: Cortical sensory loss (if parietal involvement)
6. Cerebellar: Dysmetria, dysdiadochokinesia, ataxic gait
7. Gait: Hemiparetic or ataxic pattern

---

5. Differential Diagnosis

The differential diagnosis of PML is broad and depends on the clinical context (HIV-positive vs. MS patient vs. other immunosuppression).

In HIV/AIDS Patients

In MS Patients (on Natalizumab or Other DMTs)

In Other Immunosuppressed Patients

Key Discriminators for PML

✅ Suggestive of PML:

• Subacute progressive course (weeks to months)
• Non-enhancing white matter lesions (unless IRIS)
• Involvement of subcortical U-fibres (characteristic)
• Asymmetric, multifocal distribution
• JCV PCR positive in CSF
• Immunosuppressed patient

❌ Against PML:

• Acute onset (less than 1 week)
• Ring-enhancing lesions with mass effect (consider toxoplasma, lymphoma)
• Fever, meningismus (consider other infections)
• Normal MRI (PML is almost always visible on MRI)

---

6. Investigations

Neuroimaging: MRI Brain (Gold Standard)

MRI is the cornerstone of PML diagnosis. PML has characteristic—though not pathognomonic—imaging features. [16]

Classic MRI Features of PML

Pathognomonic Feature: Subcortical U-Fibre Involvement

U-fibres (arcuate fibres) are short association fibres connecting adjacent gyri, running immediately beneath the cortex. They are relatively spared in MS but are characteristically involved in PML. [16]

• Clinical Significance: U-fibre involvement creates a sharp, scalloped border at the grey-white junction, giving a distinctive appearance.
• "Barn Door Sign": In advanced PML, large confluent lesions with U-fibre involvement can resemble an open barn door.

Imaging Evolution

• Early: Small, discrete lesions with restricted diffusion at edges
• Progressive: Expansion and coalescence of lesions
• IRIS: Development of contrast enhancement, edema, mass effect (see Management section)

Atypical Imaging Patterns

• Contrast enhancement without IRIS: Rare, suggests partial immune competence [17]
• Posterior fossa involvement: Less common but recognized
• Unilateral presentation: Can occur, though typically becomes bilateral over time
• Gray matter involvement: Rare variant (granule cell neuronopathy)

Cerebrospinal Fluid (CSF) Analysis

JC Virus PCR (Critical Diagnostic Test)

Key Points:

• False negatives: Can occur, especially early in disease or with low viral replication; repeat testing if suspicion high
• False positives: Extremely rare with modern PCR assays
• Timing: Consider repeat LP if initial negative but suspicion remains high

Routine CSF Studies

Clinical Pearl: PML is classically acellular on CSF—the "paradox" of progressive brain destruction without significant inflammation in the immunosuppressed state.

HIV Testing

Mandatory in all cases of suspected PML without known immunosuppression. HIV-associated PML remains common globally, and PML may be the presenting manifestation of previously undiagnosed HIV/AIDS. [2]

• HIV antibody/antigen test
• CD4+ T-cell count: Typically less than 200 cells/μL, often less than 50 cells/μL in HIV-PML [2]
• HIV viral load

Brain Biopsy (Rarely Required)

Indications for biopsy:

• CSF JCV PCR negative (including repeat/ultrasensitive assay) but high clinical suspicion
• Atypical imaging features raising concern for alternative diagnosis (e.g., lymphoma)
• Diagnostic uncertainty requiring definitive diagnosis to guide management

Histological findings:

1. Demyelination in multifocal areas
2. Enlarged oligodendrocytes with viral nuclear inclusions ("ground-glass" nuclei)
3. Bizarre astrocytes (enlarged, hyperchromatic, atypical nuclei)
4. Minimal to absent inflammation (in immunosuppressed state; marked inflammation in IRIS)

Immunohistochemistry: JCV-specific antibodies confirm viral antigens in infected cells

Electron microscopy: Polyomavirus particles visible in oligodendrocyte nuclei (45 nm icosahedral virions)

Additional Investigations

---

7. Diagnosis and Diagnostic Criteria

Clinical Diagnosis of PML

PML is diagnosed based on a combination of clinical, radiological, and virological criteria.

Definite PML (any of the following):

1. Brain biopsy demonstrating histopathological triad + JCV immunohistochemistry/in situ hybridization positive
2. Compatible clinical syndrome + characteristic MRI + positive CSF JCV PCR in appropriate immunosuppressed context

Probable PML:

• Compatible clinical syndrome + characteristic MRI + negative CSF JCV PCR (but suspicion remains high; consider repeat LP with ultrasensitive PCR)

Possible PML:

• Compatible clinical syndrome or characteristic MRI (but not both) + appropriate immunosuppressed context; requires further investigation

Key Diagnostic Elements

✅ Essential for diagnosis:

1. Immunosuppression (HIV, natalizumab, other iatrogenic causes)
2. Subacute progressive neurological deficits
3. MRI showing multifocal white matter lesions with U-fibre involvement, non-enhancing
4. Positive CSF JCV PCR (or brain biopsy)

---

8. Management

Critical principle: There is no specific antiviral therapy effective against JC virus. Management centers on immune reconstitution to allow the host immune system to control viral replication. [1,4]

A. HIV-Associated PML

Immediate Management

1. Initiate HAART immediately if not already on therapy, or optimize regimen if on suboptimal therapy [19]

   • Goal: Suppress HIV viral load and restore CD4+ T-cell count
   • Modern HAART regimens achieve viral suppression in > 85% within 6 months

2. Baseline assessments:

   • MRI brain (with and without contrast)
   • CSF analysis (JCV PCR, routine studies)
   • CD4 count, HIV viral load
   • Neurological examination with severity scoring

Monitoring

• Clinical assessment: Weekly initially, then every 2-4 weeks
• MRI surveillance: Repeat at 4-8 weeks, then every 3-6 months
• CD4 count: Monitor monthly until stable recovery
• Watch for IRIS: Typically occurs 2-8 weeks after HAART initiation (see IRIS section below)

Prognosis with HAART

• Pre-HAART era: Median survival 3-6 months; almost universally fatal [2]
• HAART era: 1-year survival approximately 50%; median survival extended to > 1 year [6,19]
• Prognostic factors:
  • "Favorable: Higher baseline CD4 (> 200), early HAART initiation, localized disease on MRI"
  • "Unfavorable: Very low CD4 (less than 50), multifocal extensive disease, delayed diagnosis"

B. Natalizumab-Associated PML

Natalizumab-associated PML is a medical emergency requiring immediate action. [3,20]

Immediate Management Protocol

Step 1: Stop Natalizumab Immediately

• Discontinue further infusions
• Inform patient of diagnosis and prognosis

Step 2: Plasma Exchange (PLEX) or Immunoadsorption

• Goal: Rapidly remove natalizumab from circulation (natalizumab has long half-life: ~16 days)
• Regimen: 3-5 sessions over 5-10 days [20]
• Mechanism: Accelerates immune reconstitution by removing the α4-integrin blockade, allowing lymphocytes to re-enter CNS
• Evidence: Observational data suggest improved outcomes with PLEX, though high risk of IRIS [20]

Step 3: Monitor for IRIS (see dedicated IRIS section below)

• Serial clinical assessment (daily initially)
• Repeat MRI at 1-2 weeks, then weekly for first month
• Consider prophylactic corticosteroids (controversial; see IRIS section)

Specific Considerations

• Timing of PLEX: Earlier is likely better, though balanced against IRIS risk
• Glucocorticoids: Use is contentious; may be considered for severe IRIS but risks prolonging viral replication
• Supportive care: Antiepileptics if seizures, VTE prophylaxis, rehabilitation

Prognosis with Natalizumab-PML

• Survival: Approximately 75-80% survive [3,20]
• Disability: Survivors often have significant residual deficits; only 20-30% return to pre-PML functional status [20]
• Prognostic factors:
  • "Favorable: Lower baseline EDSS (disability score), smaller lesion volume, early detection (e.g., asymptomatic radiographic detection)"
  • "Unfavorable: Multifocal extensive disease, brainstem involvement, delayed recognition"

C. PML Associated with Other Immunosuppressive Therapies

General principle: Withdraw offending agent(s) and allow immune reconstitution. [9]

D. Immune Reconstitution Inflammatory Syndrome (IRIS)

IRIS is a paradoxical clinical and radiological worsening occurring as immune function is restored (e.g., after HAART initiation or natalizumab cessation). [17,21]

Pathophysiology of IRIS

As the immune system recovers:

1. Restored T-cell function allows recognition of widespread JCV antigens in the CNS
2. Vigorous inflammatory response to viral antigens
3. Inflammation causes edema, mass effect, contrast enhancement on MRI
4. Clinical worsening despite reduction in viral load

Clinical Features of PML-IRIS

• Timing: Typically 2-8 weeks after immune reconstitution (can be earlier or later)
• Symptoms: Worsening neurological deficits, new seizures, headache, confusion
• Severity: Ranges from mild to life-threatening (cerebral edema, herniation)

Diagnostic Criteria for PML-IRIS [17]

1. Worsening neurological symptoms after initiation of immune-restorative therapy
2. MRI changes:
   • New or increased contrast enhancement
   • New or increased edema/mass effect
   • Expansion of lesions
3. Exclusion of alternative causes (e.g., new infection, progression of underlying disease)

MRI Features of IRIS

Management of PML-IRIS [17,21]

The central dilemma: Need immune function to control JCV, but immune response causes inflammation and potential herniation.

Step 1: Assess Severity

• Mild: Minor clinical worsening, minimal edema on MRI
• Moderate: Significant clinical worsening, moderate edema
• Severe: Life-threatening edema, impending herniation, seizures, altered consciousness

Step 2: Glucocorticoid Therapy (Mainstay)

Step 3: Additional Measures for Severe IRIS

• Osmotic therapy: Mannitol or hypertonic saline for raised ICP
• Antiepileptics: Levetiracetam or other agent if seizures
• Neurosurgical consultation: If impending herniation; rarely, decompressive craniotomy required
• Continue HAART: Do not stop HAART in HIV-IRIS (risk of viral rebound outweighs IRIS risk)

Step 4: Long-term Monitoring

• MRI every 4-8 weeks initially, then every 3-6 months
• Gradual steroid taper over months
• Monitor for PML progression vs. IRIS inflammation

Outcomes of IRIS

• IRIS is a marker of immune reconstitution and, paradoxically, may be associated with better long-term survival than non-IRIS cases (implies immune competence) [21]
• However, severe IRIS can cause death or severe disability from mass effect
• Careful balancing of immunosuppression (steroids) vs. immune reconstitution is critical

E. Experimental and Emerging Therapies

Given the lack of specific antivirals, several experimental approaches have been explored:

1. Pembrolizumab (Anti-PD-1 Checkpoint Inhibitor)

• Mechanism: Blocks PD-1 receptor on T-cells, enhancing anti-viral T-cell response ("releasing the brakes" on immune system)
• Evidence: Case series and case reports showing benefit in refractory PML, particularly in non-HIV patients [22]
• Use: Reserved for compassionate use in life-threatening, refractory PML
• Risks: Immune-related adverse events, including severe IRIS-like reactions
• Dosing: Variable regimens reported (e.g., 2 mg/kg every 3 weeks)

2. Interleukin-7 (IL-7)

• Mechanism: Boosts T-cell expansion and function
• Evidence: Small case series with mixed results
• Status: Experimental; not widely available

3. Cytarabine, Cidofovir, Mirtazapine

• Historical: Previously tried based on in vitro data
• Evidence: Clinical trials and observational studies showed no benefit [1]
• Current status: Not recommended

4. 5-HT2a Receptor Antagonists (Mirtazapine, Risperidone)

• Rationale: JCV may use 5-HT2a receptors for cell entry
• Evidence: Observational studies showed no benefit [1]
• Current status: Not recommended

F. Supportive and Symptomatic Management

---

9. Complications

PML and its treatment (particularly IRIS) can result in significant complications:

---

10. Prognosis & Outcomes

Survival Rates by Population

Functional Outcomes

Even among survivors, outcomes are often poor:

• Return to pre-PML function: Only 20-30% [20]
• Moderate-severe disability: 50-60%
• Dependent for ADLs: 30-40%

Prognostic Factors

Favorable:

• Early diagnosis (smaller lesion burden)
• Higher baseline immune function (CD4 > 200 in HIV, lower baseline disability in MS)
• Localized disease on MRI
• Younger age
• Rapid immune reconstitution

Unfavorable:

• Extensive, multifocal disease
• Brainstem or cerebellar involvement
• Very low CD4 (less than 50) in HIV
• Delayed diagnosis
• Inability to restore immune function
• Severe IRIS with mass effect

Long-Term Sequelae

Survivors often face:

• Permanent motor deficits (hemiparesis, ataxia)
• Cognitive impairment and executive dysfunction
• Visual field deficits
• Seizure disorder (requiring long-term antiepileptics)
• Psychological impact (depression, anxiety)
• Reduced quality of life

---

11. Prevention & Risk Mitigation

Primary Prevention

No vaccine or prophylaxis exists for PML. Prevention focuses on risk stratification and monitoring in at-risk populations.

Natalizumab Risk Stratification Strategy [3]

Three key risk factors determine PML risk in natalizumab-treated MS patients:

1. JCV antibody status (presence/absence)
2. Duration of natalizumab therapy (particularly > 24 months)
3. Prior immunosuppressant use (e.g., azathioprine, mitoxantrone)

Risk Mitigation Strategies:

• Baseline JCV antibody testing before natalizumab initiation
• Serial JCV antibody testing every 6 months (seronegative patients can seroconvert)
• Consider alternative DMT in high-risk patients (JCV Ab+, > 24 months)
• Extended interval dosing (e.g., every 6 weeks instead of 4 weeks): reduces PML risk, though may reduce efficacy [23]
• MRI surveillance: Every 3-6 months in high-risk patients to detect asymptomatic PML

Asymptomatic PML Detection

In high-risk patients on natalizumab:

• Serial MRI (every 3-6 months) may detect asymptomatic radiographic changes before clinical symptoms
• Early detection and intervention associated with better outcomes [20]

HIV-Associated PML Prevention

• Early HAART initiation in all HIV-positive patients (prevents immunosuppression)
• Adherence to HAART (prevents viral rebound and CD4 decline)
• Regular CD4 monitoring in HIV patients not on HAART (trigger for initiation if less than 350, urgent if less than 200)

General Immunosuppression

• Use minimum effective immunosuppression in transplant, autoimmune disease, malignancy
• Monitor lymphocyte counts with lymphocyte-depleting agents (e.g., rituximab, dimethyl fumarate)
• Awareness: High index of suspicion for PML in any immunosuppressed patient with subacute neurological decline

---

12. Key Guidelines and Consensus Statements

---

13. Common Exam Questions & Viva Points

Frequently Asked Questions

1. "What are the causes of PML?"

Model Answer: "PML is caused by reactivation of the JC virus, a ubiquitous polyomavirus, in the setting of severe immunosuppression. The major causes include HIV/AIDS with CD4 counts below 200, iatrogenic immunosuppression—particularly with natalizumab in multiple sclerosis patients—and haematological malignancies treated with agents like rituximab and fludarabine. Other causes include solid organ transplantation and, rarely, other disease-modifying therapies for autoimmune diseases."

2. "How would you investigate a patient with suspected PML?"

Model Answer: "I would take a systematic approach. First, confirm immunosuppression status—HIV test if unknown, review of medications. Second, MRI brain with and without contrast, looking for characteristic multifocal white matter lesions with U-fibre involvement, typically non-enhancing. Third, lumbar puncture for CSF JCV PCR, which has high specificity and sensitivity of 70-90%, higher with ultrasensitive assays. The CSF is typically acellular with normal protein and glucose. If these are concordant, the diagnosis is confirmed. If JCV PCR is negative but suspicion is high, I would consider repeat lumbar puncture or, rarely, brain biopsy."

3. "What is your management of natalizumab-associated PML?"

Model Answer: "Natalizumab-associated PML is a neurological emergency. Management priorities are: first, immediately stop natalizumab; second, arrange urgent plasma exchange—typically 3-5 sessions over 5-10 days—to rapidly remove the drug from circulation and facilitate immune reconstitution; third, close monitoring for IRIS with serial clinical assessments and MRI, as IRIS occurs in up to 30% and can cause life-threatening cerebral edema. If IRIS develops, I would treat with high-dose corticosteroids, balancing anti-inflammatory effects against the need for immune function to control the virus. Supportive care including antiepileptics if needed and early involvement of neurorehabilitation are also critical."

4. "What are the MRI features that distinguish PML from MS relapse?"

Model Answer: "Several MRI features help distinguish PML from MS relapse. PML lesions typically involve subcortical U-fibres, creating a sharp scalloped border at the grey-white junction, whereas MS plaques classically spare U-fibres. PML lesions are usually non-enhancing, whereas active MS plaques often show gadolinium enhancement. PML shows restricted diffusion on DWI at the leading edge, indicating active viral infection. PML lesions are often large, asymmetric, and confluent, whereas MS plaques are typically smaller and more discrete. Clinically, PML causes subacute progressive decline, whereas MS relapses are acute with potential for recovery."

5. "What is IRIS in the context of PML, and how is it managed?"

Model Answer: "IRIS—immune reconstitution inflammatory syndrome—is a paradoxical clinical and radiological worsening that occurs when immune function is restored, typically 2-8 weeks after starting HAART or stopping natalizumab. The recovering immune system mounts a vigorous inflammatory response to widespread JCV antigens in the brain, causing edema, mass effect, and contrast enhancement on MRI that was previously absent. Clinically, patients worsen despite falling viral loads. Management requires careful balancing: corticosteroids are the mainstay, with doses ranging from oral prednisolone for mild cases to high-dose IV methylprednisolone for severe cases with mass effect. We must avoid over-suppressing the immune response, as immune function is needed to ultimately control the virus. Severe cases may require osmotic therapy for raised ICP and, rarely, neurosurgical decompression."

Viva Opening Statement

"Progressive multifocal leukoencephalopathy is a severe demyelinating disease of the CNS caused by JC virus reactivation in immunocompromised individuals, most commonly in HIV/AIDS with CD4 counts below 200 or in MS patients treated with natalizumab. It presents with subacute progressive neurological deficits evolving over weeks to months. Diagnosis relies on characteristic MRI findings—multifocal non-enhancing white matter lesions with U-fibre involvement—and positive CSF JCV PCR. There is no specific antiviral; management centers on immune reconstitution by initiating HAART in HIV patients or stopping natalizumab and performing plasma exchange in MS patients. The major complication is IRIS, requiring corticosteroid therapy. Prognosis is guarded, with 1-year survival around 50% in HIV-PML and 75-80% in natalizumab-PML, though survivors often have significant disability."

Common Mistakes to Avoid

❌ Mistakes that fail candidates:

• Failing to recognize PML as a differential in immunosuppressed patients with subacute neurological decline
• Confusing PML with MS relapse (PML does not enhance unless IRIS; involves U-fibres)
• Not knowing that there is no specific antiviral for JCV; management is immune reconstitution
• Recommending continuing natalizumab or delaying PLEX in natalizumab-PML
• Not recognizing IRIS as a potential complication requiring corticosteroids
• Stating that PML is always fatal (prognosis has improved with HAART and PLEX)
• Missing the characteristic MRI feature of U-fibre involvement

---

14. Patient & Layperson Explanation

What is PML?

PML stands for Progressive Multifocal Leukoencephalopathy. It is a rare but serious brain infection caused by a virus called the JC virus.

How common is the JC virus?

The JC virus is actually very common—about half to three-quarters of all adults carry it, usually without knowing it. The virus normally lives harmlessly in the kidneys and bone marrow. For most people, it never causes any problems.

Why does it sometimes cause PML?

PML only occurs when the immune system is severely weakened. This can happen in people with advanced HIV/AIDS, people taking certain strong medications for diseases like multiple sclerosis (especially a drug called natalizumab or Tysabri), or people with blood cancers or organ transplants. When the immune system is weak, the JC virus can "wake up," travel to the brain, and attack the insulation around nerves (called myelin), causing damage.

What are the symptoms?

PML develops slowly over weeks or months. Symptoms depend on which parts of the brain are affected, but common signs include:

• Weakness or clumsiness on one side of the body
• Difficulty speaking or finding words
• Changes in vision (such as losing half of your vision on each side)
• Memory problems or personality changes
• Problems with balance or coordination

Unlike a stroke, which happens suddenly, PML gets progressively worse over time.

How is it diagnosed?

Doctors use an MRI scan of the brain, which shows characteristic white patches in the brain's white matter. They also perform a spinal tap (lumbar puncture) to test the fluid around the brain and spinal cord for the JC virus. If the virus is found and the MRI shows the characteristic pattern, the diagnosis is confirmed.

Can it be treated?

Unfortunately, there is no drug that can kill the JC virus directly. The only way to fight PML is to restore the immune system so it can control the virus itself.

• In people with HIV: Starting or improving HIV treatment (called HAART) to boost the immune system.
• In people on natalizumab or other drugs: Stopping the medication immediately and, in some cases, using a procedure called plasma exchange to quickly remove the drug from the bloodstream.

What is IRIS?

As the immune system recovers, it sometimes "overreacts" to the virus in the brain, causing swelling and inflammation. This is called IRIS (Immune Reconstitution Inflammatory Syndrome). It can temporarily make symptoms worse. If this happens, doctors may give steroids to reduce the inflammation while still allowing the immune system to fight the virus.

What is the outlook?

PML is a serious condition. With treatment to restore the immune system, about half of people with HIV-related PML and about three-quarters of people with natalizumab-related PML survive. However, many survivors have lasting problems such as weakness, difficulty walking, memory issues, or vision problems. Early detection and treatment improve the chances of a better outcome.

Can PML be prevented?

For people with HIV, the best prevention is starting HIV treatment early to keep the immune system strong. For people considering natalizumab, doctors assess the risk using a blood test for JC virus antibodies and recommend regular MRI scans to catch any problems early. People at high risk may choose a different medication.

---

15. References

1. Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17(1):37-51. doi:10.1038/s41582-020-00427-y

2. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430-1438. doi:10.1212/WNL.0b013e31828c2fa1

3. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880. doi:10.1056/NEJMoa1107829

4. Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis. 2009;48(10):1459-1466. doi:10.1086/598335

5. Pavlovic D, Patera AC, Nyberg F, et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255-273. doi:10.1177/1756285615602832

6. Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199(1):77-83. doi:10.1086/595299

7. Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019;380(17):1597-1605. doi:10.1056/NEJMoa1815039

8. Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol. 2011;70(2):305-322. doi:10.1002/ana.22408

9. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35-47. doi:10.1146/annurev.med.080708.082655

10. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5(3):e1000363. doi:10.1371/journal.ppat.1000363

11. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425-437. doi:10.1016/S1474-4422(10)70040-5

12. Berger JR, Aksamit AJ. Clinical spectrum of progressive multifocal leukoencephalopathy. Clin Infect Dis. 2009;48(10):1287-1291. doi:10.1086/598044

13. Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology. 2006;66(2):262-264. doi:10.1212/01.wnl.0000194224.89193.c7

14. Bartsch T, Remmel D, Lehmbeck JT, et al. The spectrum of progressive multifocal leukoencephalopathy: a practical approach. Eur J Neurol. 2019;26(4):566-e41. doi:10.1111/ene.13906

15. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol. 2003;9 Suppl 1:88-92. doi:10.1080/13550280390194016

16. Bag AK, Curé JK, Chapman PR, et al. JC virus infection of the brain. AJNR Am J Neuroradiol. 2010;31(9):1564-1576. doi:10.3174/ajnr.A2035

17. Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009;72(17):1458-1464. doi:10.1212/01.wnl.0000343910.25117.86

18. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol. 2003;9 Suppl 1:73-80. doi:10.1080/13550280390194213

19. British HIV Association. UK national guidelines for the management of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12 Suppl 2:1-140. doi:10.1111/j.1468-1293.2011.00944_1.x

20. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438-446. doi:10.1016/S1474-4422(10)70028-4

21. Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;77(11):1061-1067. doi:10.1212/WNL.0b013e31822e55e7

22. Walter O, Treiner E, Bonneville F, et al. Treatment of progressive multifocal leukoencephalopathy with nivolumab. N Engl J Med. 2019;380(15):1674-1676. doi:10.1056/NEJMc1816198

23. Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93(15):e1452-e1462. doi:10.1212/WNL.0000000000008243